AA
KERX

ALPS Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

ALPS Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-50,296
Closed -$640K – 692
2015
Q1 		$640K Buy
+50,296
New +$647K 0.01% 207

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

ALPS Advisors's KERX Position: Q2 2015 in Review

ALPS Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 50,296 shares — an estimated $640K sold.

ALPS Advisors first reported a position in KERX in Q1 2015 and held it in 1 quarter. The position peaked at $640K in Q1 2015. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • ALPS Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • ALPS Advisors sold 50,296 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $640K.
  • ALPS Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 1 quarter.
  • ALPS Advisors's Keryx Biopharmaceuticals Inc position peaked at $640K in Q1 2015.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on ALPS Advisors's 13F filing for Q2 2015, filed 12 Aug 2015.